An object of the present invention is to provide a compound useful as a therapeutic drug for an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis of SLE patients by suppressing immune cell function by inhibiting proliferation of activated T cells and production of interferon alpha (IFN-α).

The present invention provides a compound represented by formula (I):

##STR00001##

wherein R.sup.1, R.sup.2 and R.sup.3 are the same as defined in the specification,
or a pharmaceutically acceptable salt thereof.

An object of the present invention is to provide a compound useful as a therapeutic drug for an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis of SLE patients by suppressing immune cell function by inhibiting proliferation of activated T cells and production of interferon alpha (IFN-α).

The present invention provides a compound represented by formula (I):

##STR00001##

wherein R.sup.1, R.sup.2 and R.sup.3 are the same as defined in the specification,
or a pharmaceutically acceptable salt thereof.

The present invention provides a compound, a salt thereof, or a prodrug thereof as a compound effective for preventing and/or treating fibrosis, the compound being represented by formula (1)

##STR00001##

(wherein A is an optionally substituted benzene ring; B is optionally substituted aryl or optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom, of Y′ is a single or double bond when Y is a carbon atom, or of Y′ is a single bond when Y is a nitrogen atom; each R.sup.1 independently represents lower alkyl, or two R.sup.1s may be bound to each other to form a spiro ring or a crosslinked structure, or two R.sup.1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (R.sup.1).sub.p is oxo).

The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R.sup.1a, R.sup.2a, R.sup.3a, A.sup.1, A.sup.2, A.sup.3, R.sup.1b, R.sup.2b, R.sup.3b, B.sup.1, and B.sup.2 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Gaucher's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

The application is directed to compounds of formulae (IA) and (IB) and their salts and solvates, wherein R.sup.1a, R.sup.2a, R.sup.3a, A.sup.1, A.sup.2, A.sup.3, R.sup.1b, R.sup.2b, R.sup.3b, B.sup.1, and B.sup.2 are as set forth in the specification, as well as to methods for their preparation, pharmaceutical compositions comprising the same, and use thereof for the treatment and/or prevention of, e.g., lysosomal storage diseases, such as Gaucher's disease, and α-synucleinopathies, such as Parkinson's disease.

##STR00001##

The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.

The invention relates to methods and compositions for the treatment or prevention of Flaviviridae infections. In particular, the invention relates to an LSD1 inhibitor for use in treating or preventing Flaviviridae infections, including hepatitis C virus infections.

Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.

Disclosed are compounds that may be used to inhibit the action of fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MAGL) or dual FAAH/MAGL.

The present disclosure is related to the field of enzyme inhibitors, and in particular to a hydroxamic acid derivative, a method for producing the same and use thereof. The hydroxamic acid group of the hydroxamic acid derivative can be chelated with zinc ions in the LpxC active area, and the derivative has a hydrophobic side chain which can bind to hydrophic channels in the enzyme LpxC. These guarantee that the hydroxamic acid derivative has good bactericidal activity against Gram-negative bacteria and low toxicity. The present disclosure also provides a method for producing the hydroxamic acid derivative, which requires a shorter reaction time and can provide the derivative with a high yield.